Data from the Phase III FRONTIER3 trial found that 98% of caregivers prefer Mim8 for hemophilia A over other treatments.

Using “cure” to refer to “obtaining a normal life” also fits — if you ignore previously lost education, career opportunities ...

CSL Limited (OTC:CSLLY) and uniQure Inc (NASDAQ:QURE) announced the four-year results from the pivotal HOPE-B study ...

Novo Nordisk’s bispecific antibody Mim8 prevented bleeding events and caused no adverse safety events in the Phase III ...

Novo Nordisk has bolstered the case for its near-approval hemophilia A drug candidate Mim8, linking the prospect to ...

With hemophilia, it's easy to assume that joint pain is caused by bleeding. But that's not always the case, columnist G ...

CSL (ASX: CSL; USOTC: CSLLY) has unveiled four-year results from its pivotal HOPE-B study, demonstrating the long-term ...

Hemophilia A patients with self-described problem joints were found to have worse clinical outcomes, with more pain, in a new study.

Global biotechnology leader CSL Behring (ASX:CSL; USOTC: CSLLY (OTC:CSLLY)) announced the four-year results from the HOPE-B ...

Growing advancements in haemophilia treatment underscore a significant shift toward targeted and long-lasting therapeutic ...

Hemophilia B Market Outlook 2025-2035: The 7 major hemophilia B market reached a value of USD 10.0 Billion in 2024. Looking forward, IMARC Group expects the 7MM to reach USD 24.7 Billion by 2035, ...